PSC associated inflammatory bowel disease: a distinct entity

Expert Rev Gastroenterol Hepatol. 2022 Feb;16(2):129-139. doi: 10.1080/17474124.2022.2031979. Epub 2022 Feb 2.

Abstract

Introduction: Primary sclerosing cholangitis (PSC) is a rare, chronic, and progressive cholestatic disease involving intra- and/or extrahepatic bile ducts. PSC in many patients results in end-stage liver diseases. Nearly 60% of the PSC patients suffer from concomitant inflammatory bowel diseases (IBDs). Classically, IBDs are divided into two principle types: Crohn's disease (CD) and ulcerative colitis (UC). However, with growing knowledge, PSC-associated IBD (PSC-IBD) seems to be a rather distinct entity with specific genetics, clinical, and microbiota characteristics.

Areas covered: In this article, we aim to review the unique characteristics of PSC-IBD from clinical, genetic, and microbiota point of view.

Expert opinion: PSC-IBD's unique characteristics contribute to the notion that it could be a distinct entity. Acknowledgment of PSC-IBD as a novel entity necessitates designing new clinical guidelines for diagnosis and developing novel therapies.

Keywords: PSC associated IBD; PSC-IBD; Primary sclerosing cholangitis; inflammatory bowel diseases.

Publication types

  • Review

MeSH terms

  • Cholangitis, Sclerosing / complications*
  • Cholangitis, Sclerosing / genetics
  • Cholangitis, Sclerosing / microbiology
  • Gastrointestinal Microbiome
  • Humans
  • Inflammatory Bowel Diseases / complications*
  • Inflammatory Bowel Diseases / genetics
  • Inflammatory Bowel Diseases / microbiology